Showing results (991-1000 of 1,038) with videos related to

Sort By:
Pageof 104
Annals of Neurology|August 12, 2000
Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C geneG Bonne, E Mercuri, A Muchir, et al.
Clinical Trials (London, England)|December 1, 2020
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)Ethan Basch, Claus Becker, Lauren J Rogak, et al.
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2024
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid HemangioendotheliomaScott M Schuetze, Karla V Ballman, Rachel Heise, et al.
Frontiers in Oncology|September 15, 2022
Adjuvant crizotinib in high-risk uveal melanoma following definitive therapyShaheer Khan, Jose Lutzky, Alexander N Shoushtari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Phase II study of sorafenib in patients with metastatic or recurrent sarcomasRobert G Maki, David R D'Adamo, Mary L Keohan, et al.
The Oncologist|October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue SarcomasRodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.
Cancer Discovery|June 18, 2014
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapyHikmat Al-Ahmadie, Gopa Iyer, Marcel Hohl, et al.
Nature Genetics|January 9, 2023
Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimensYiping Wang, Joy Linyue Fan, Johannes C Melms, et al.
Molecular Cancer Therapeutics|June 12, 2015
Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream TeamPatricia M LoRusso, Scott A Boerner, Mary Jo Pilat, et al.
Pageof 104